stockrow
Saturday 7 November 2026
Export ARDX’s income statement to Excel — free account
Ardelyx, Inc.
ARDX Healthcare Biotechnology
Ardelyx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $407.3 million, up 22.1% from fiscal 2024.
- Revenue
- +15.7%
- EPS
- +27.5%
- Free cash flow
- +938.8%
- Total debt
- +24.8%
Quarter to September 2026, against a year earlier
2.86
0.13
−4.35%
Follow ARDX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.83 | 2.81 | 3.44 | 3.45 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
393.84 | (197.71) | (45.68) | 67.07 | |
P/B ratio |
5.21 | 8.49 | 9.91 | 8.42 | |
Price to Tangible BV |
5.21 | 8.49 | 9.91 | 8.42 | |
EV/Sales |
1.81 | 2.80 | 3.43 | 3.36 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(54.73) | (72.87) | (40.40) | (32.26) | |
EV/FCF |
(53.21) | (70.44) | (39.07) | (31.16) | |
Quick Ratio |
2.96 | 2.89 | 2.93 | 3.80 | |
Current Ratio |
3.45 | 3.34 | 3.49 | 4.31 | |
Net Debt/EBITDA |
(7.10) | 2.54 | 1.08 | (10.27) | |
Debt/Assets |
42.95% | 43.73% | 40.34% | 40.44% | |
Debt/Equity |
1.54 | 1.69 | 1.37 | 1.21 | |
Asset Turnover |
0.87 | 0.86 | 0.94 | 0.87 | |
Operating CF/Net income |
(2.95) | 0.38 | 0.86 | (51.48) | |
Capex/Depreciation |
0.00 | (0.02) | (0.08) | (0.39) | |
Interest Coverage |
0.55 | (2.00) | (4.74) | 0.67 | |
Research and Development Expense of Revenue |
19.74% | 21.59% | 21.37% | 18.25% | |
Selling, General and Administrative Expense of Revenue |
73.55% | 83.92% | 108.25% | 69.01% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
11.83% | 12.67% | 14.99% | 9.94% | |
Graham Net Nets |
0.02 | 0.01 | 0.02 | 0.03 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.52%) | (4.39%) | (3.91%) | (4.36%) | |
Free Cash Flow Yield |
(1.87%) | (1.42%) | (2.55%) | (3.13%) | |
Revenue per Share |
0.51 | 0.49 | 0.38 | 0.52 | |
Operating CF per Share |
0.01 | (0.03) | (0.13) | 0.09 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.01 | (0.03) | (0.13) | 0.09 | |
Cash per Share |
1.14 | 1.14 | 0.97 | 1.10 | |
Shareholders Equity per Share |
0.66 | 0.60 | 0.60 | 0.69 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.66 | 0.60 | 0.60 | 0.69 | |
Free Cash Flow |
2.17 | (6.41) | (32.31) | 20.59 | |
Working Capital |
313.58 | 309.71 | 272.30 | 293.71 | |
Capital Expenditures |
0.00 | (0.01) | (0.07) | (0.36) | |
Net Current Asset Value |
17.91 | 15.05 | 25.99 | 47.66 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
85.03 | 81.45 | 64.65 | 64.78 | |
Average Payables |
26.02 | 30.05 | 20.96 | 17.62 | |
Average Inventory |
24.81 | 24.07 | 23.26 | 19.45 | |
Average Assets |
536.85 | 521.33 | 457.35 | 468.68 | |
Average Common Equity |
159.16 | 144.27 | 147.15 | 170.12 |
Columns are period end dates · fundamentals updated 5 Nov 2026